Effectiveness of liposomal paclitaxel against MCF-7 breast cancer cells.

Paclitaxel is an effective chemotherapeutic agent that is widely used for the treatment of several cancers, including breast, ovarian, and non-small-cell lung cancer. Due to its high lipophilicity, paclitaxel is difficult to administer and requires solubilization with Cremophor EL (polyethoxylated castor oil) and ethanol, which often lead to adverse side effects, including life-threatening anaphylaxis. Incorporation of paclitaxel in dimyristoylphosphatidylcholine:dimyristoylphosphatidylglycerol (DPPC:DMPG) liposomes can facilitate its delivery to cancer cells and eliminate the adverse reactions associated with the Cremophor EL vehicle. Accordingly, the effectiveness of liposomal paclitaxel on MCF-7 breast cancer cells was examined. The results from this study showed that (i) the lipid components of the liposomal formulation were nontoxic, (ii) the cytotoxic effects of liposomal paclitaxel were improved when compared with those seen with conventional paclitaxel, and (iii) the intracellular paclitaxel levels were higher in MCF-7 cells treated with the liposomal paclitaxel formulation. The results of these studies showed that delivery of paclitaxel as a liposomal formulation could be a promising strategy for enhancing its chemotherapeutic effects.

[1]  S. Warmann,et al.  The BH3 mimetic ABT-737 increases treatment efficiency of paclitaxel against hepatoblastoma , 2011, BMC Cancer.

[2]  Chien-Chih Chiu,et al.  Subamolide E from Cinnamomum subavenium induces sub-G1 cell-cycle arrest and caspase-dependent apoptosis and reduces the migration ability of human melanoma cells. , 2011, Journal of agricultural and food chemistry.

[3]  H. Caron,et al.  Different anthracycline derivates for reducing cardiotoxicity in cancer patients. , 2010, The Cochrane database of systematic reviews.

[4]  J. Ciccolini,et al.  Liposome-encapsulated anticancer drugs: still waiting for the magic bullet? , 2009, Current Medicinal Chemistry.

[5]  Stephen S. Taylor,et al.  How do anti-mitotic drugs kill cancer cells? , 2009, Journal of Cell Science.

[6]  E. Miele,et al.  Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer , 2009, International journal of nanomedicine.

[7]  G. Scambia,et al.  New taxanes in development , 2008 .

[8]  T. Yang,et al.  Antitumor Effect of Paclitaxel-Loaded PEGylated Immunoliposomes Against Human Breast Cancer Cells , 2007, Pharmaceutical Research.

[9]  H. Brem,et al.  Paclitaxel: a review of adverse toxicities and novel delivery strategies , 2007, Expert opinion on drug safety.

[10]  T. Ganesh.  Improved biochemical strategies for targeted delivery of taxoids. , 2007, Bioorganic & medicinal chemistry.

[11]  M. Nakashima,et al.  Determination of paclitaxel in human and rat blood samples after administration of low dose paclitaxel by HPLC-UV detection. , 2007, Biomedical chromotography.

[12]  Y. Vander Heyden,et al.  Preparation and evaluation of paclitaxel-containing liposomes. , 2007, Die Pharmazie.

[13]  Khaled Greish,et al.  Enhanced permeability and retention of macromolecular drugs in solid tumors: A royal gate for targeted anticancer nanomedicines , 2007, Journal of drug targeting.

[14]  R. Govindan,et al.  Novel formulations of taxanes: a review. Old wine in a new bottle? , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  P. Giannakakou,et al.  Resistance to Microtubule-Stabilizing Drugs Involves Two Eventse: β-Tubulin Mutation in One Allele Followed by Loss of the Second Allele , 2005, Cell cycle.

[16]  J. Verweij,et al.  Paclitaxel repackaged in an albumin-stabilized nanoparticle: handy or just a dandy? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  S. Feng,et al.  Effects of lipid chain unsaturation and headgroup type on molecular interactions between paclitaxel and phospholipid within model biomembrane. , 2005, Journal of colloid and interface science.

[18]  P. Wright,et al.  Flavopiridol Sensitivity of Cancer Cells Isolated from Ascites and Pleural Fluids , 2005, Clinical Cancer Research.

[19]  Leslie Wilson,et al.  βIII-Tubulin Induces Paclitaxel Resistance in Association with Reduced Effects on Microtubule Dynamic Instability* , 2005, Journal of Biological Chemistry.

[20]  O. Katare,et al.  Liposomal drug delivery systems--clinical applications. , 2005, Acta pharmaceutica.

[21]  Hanna Parnas,et al.  Mathematical modeling and optimization of drug delivery from intratumorally injected microspheres. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  Michael O'Leary,et al.  Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. , 2004, The oncologist.

[23]  S. Feng,et al.  Effects of lipid chain length on molecular interactions between paclitaxel and phospholipid within model biomembranes. , 2004, Journal of colloid and interface science.

[24]  J. Verweij,et al.  Pharmacological Effects of Formulation Vehicles , 2003, Clinical pharmacokinetics.

[25]  S. Urien,et al.  Weekly administration of paclitaxel: theoretical and clinical basis. , 2002, Critical reviews in oncology/hematology.

[26]  Z. Suntres.  Role of antioxidants in paraquat toxicity. , 2002, Toxicology.

[27]  D. Aggarwal,et al.  Paclitaxel and its formulations. , 2002, International journal of pharmaceutics.

[28]  John D. Potter,et al.  Flow cytometric analysis of the cell cycle phase specificity of DNA damage induced by radiation, hydrogen peroxide and doxorubicin. , 2002, Carcinogenesis.

[29]  J. Mendelsohn,et al.  Differential modulation of paclitaxel-mediated apoptosis by p21Waf1 and p27Kip1 , 2000, Oncogene.

[30]  F. Dosio,et al.  Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing water-soluble prodrugs of paclitaxel. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[31]  R. Winter,et al.  Interaction of the anticancer agent Taxol (paclitaxel) with phospholipid bilayers. , 1999, Journal of biomedical materials research.

[32]  F. Fitzpatrick,et al.  Taxane-mediated gene induction is independent of microtubule stabilization: induction of transcription regulators and enzymes that modulate inflammation and apoptosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[33]  T. Fojo,et al.  Paclitaxel-resistant Human Ovarian Cancer Cells Have Mutant β-Tubulins That Exhibit Impaired Paclitaxel-driven Polymerization* , 1997, The Journal of Biological Chemistry.

[34]  L. Lindner,et al.  Factors affecting drug release from liposomes. , 2010, Current opinion in drug discovery & development.

[35]  Vladimir P Torchilin,et al.  Current trends in liposome research. , 2010, Methods in molecular biology.

[36]  A. Safavy.  Recent developments in taxane drug delivery. , 2008, Current drug delivery.